A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer

Reury P. Perng, Jen F. Shih, Yuh M. Chen, Francois M. Delgado, Chun M. Tsai, Kuo C. Chou, Jacqueline M. Liu, Ming S. Chern, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Weekly vinorelbine injection with cisplatin had been used in treatment of non-small-cell lung cancer. We performed a phase II trial to evaluate the efficacy and toxicity of a new schedule of vinorelbine and cisplatin in patients with previously untreated, inoperable (stage IIIB or stage IV) non- small-cell lung cancer. From April 1996 to May 1997, 52 patients were enrolled for study, and 50 patients were eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine, 30 mg/m2, intravenously on days 1 and 5 of a 21-day cycle, and cisplatin 100 mg/m2 (reduced to 80 mg/m2 after the first seven patients) given on day 1. A total of 211 treatment courses were administered; the median number of cycles administered per patient was 4.5 (range: 1-6), the median dose intensity for vinorelbine was 16.9 mg/m2/week (84.4%), whereas that of cisplatin was 22.8 mg/m2/week (84.7%). Twenty-five patients responded to therapy for an overall response rate of 50%; one patient attained a complete response (2%). The main toxicities were vomiting, myelosuppression, and diarrhea, which included World Health Organization grade 3 or 4 nausea/vomiting (58% patients), anemia (41% patients), neutropenia (12% patients), and diarrhea (14%). The median duration of responses was 9 months. The median time to disease progression was 6.8 months (range 0.4-18.1 months). Median survival was 13 months, and 54% of patients were alive at 1 year. We conclude that this new schedule of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)60-64
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number1
DOIs
Publication statusPublished - Feb 1 2000
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Vomiting
vinorelbine
Diarrhea
Appointments and Schedules
Therapeutics
Neutropenia
Nausea
Disease Progression
Anemia
Injections
Survival

Keywords

  • Cisplatin
  • Non-small-cell lung cancer
  • Phase II trial
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer. / Perng, Reury P.; Shih, Jen F.; Chen, Yuh M.; Delgado, Francois M.; Tsai, Chun M.; Chou, Kuo C.; Liu, Jacqueline M.; Chern, Ming S.; Whang-Peng, Jacqueline.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 1, 01.02.2000, p. 60-64.

Research output: Contribution to journalArticle

Perng, Reury P. ; Shih, Jen F. ; Chen, Yuh M. ; Delgado, Francois M. ; Tsai, Chun M. ; Chou, Kuo C. ; Liu, Jacqueline M. ; Chern, Ming S. ; Whang-Peng, Jacqueline. / A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2000 ; Vol. 23, No. 1. pp. 60-64.
@article{1227d9c996a84ae0bce4ce6cd83562e7,
title = "A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer",
abstract = "Weekly vinorelbine injection with cisplatin had been used in treatment of non-small-cell lung cancer. We performed a phase II trial to evaluate the efficacy and toxicity of a new schedule of vinorelbine and cisplatin in patients with previously untreated, inoperable (stage IIIB or stage IV) non- small-cell lung cancer. From April 1996 to May 1997, 52 patients were enrolled for study, and 50 patients were eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine, 30 mg/m2, intravenously on days 1 and 5 of a 21-day cycle, and cisplatin 100 mg/m2 (reduced to 80 mg/m2 after the first seven patients) given on day 1. A total of 211 treatment courses were administered; the median number of cycles administered per patient was 4.5 (range: 1-6), the median dose intensity for vinorelbine was 16.9 mg/m2/week (84.4{\%}), whereas that of cisplatin was 22.8 mg/m2/week (84.7{\%}). Twenty-five patients responded to therapy for an overall response rate of 50{\%}; one patient attained a complete response (2{\%}). The main toxicities were vomiting, myelosuppression, and diarrhea, which included World Health Organization grade 3 or 4 nausea/vomiting (58{\%} patients), anemia (41{\%} patients), neutropenia (12{\%} patients), and diarrhea (14{\%}). The median duration of responses was 9 months. The median time to disease progression was 6.8 months (range 0.4-18.1 months). Median survival was 13 months, and 54{\%} of patients were alive at 1 year. We conclude that this new schedule of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced non-small-cell lung cancer.",
keywords = "Cisplatin, Non-small-cell lung cancer, Phase II trial, Vinorelbine",
author = "Perng, {Reury P.} and Shih, {Jen F.} and Chen, {Yuh M.} and Delgado, {Francois M.} and Tsai, {Chun M.} and Chou, {Kuo C.} and Liu, {Jacqueline M.} and Chern, {Ming S.} and Jacqueline Whang-Peng",
year = "2000",
month = "2",
day = "1",
doi = "10.1097/00000421-200002000-00017",
language = "English",
volume = "23",
pages = "60--64",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer

AU - Perng, Reury P.

AU - Shih, Jen F.

AU - Chen, Yuh M.

AU - Delgado, Francois M.

AU - Tsai, Chun M.

AU - Chou, Kuo C.

AU - Liu, Jacqueline M.

AU - Chern, Ming S.

AU - Whang-Peng, Jacqueline

PY - 2000/2/1

Y1 - 2000/2/1

N2 - Weekly vinorelbine injection with cisplatin had been used in treatment of non-small-cell lung cancer. We performed a phase II trial to evaluate the efficacy and toxicity of a new schedule of vinorelbine and cisplatin in patients with previously untreated, inoperable (stage IIIB or stage IV) non- small-cell lung cancer. From April 1996 to May 1997, 52 patients were enrolled for study, and 50 patients were eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine, 30 mg/m2, intravenously on days 1 and 5 of a 21-day cycle, and cisplatin 100 mg/m2 (reduced to 80 mg/m2 after the first seven patients) given on day 1. A total of 211 treatment courses were administered; the median number of cycles administered per patient was 4.5 (range: 1-6), the median dose intensity for vinorelbine was 16.9 mg/m2/week (84.4%), whereas that of cisplatin was 22.8 mg/m2/week (84.7%). Twenty-five patients responded to therapy for an overall response rate of 50%; one patient attained a complete response (2%). The main toxicities were vomiting, myelosuppression, and diarrhea, which included World Health Organization grade 3 or 4 nausea/vomiting (58% patients), anemia (41% patients), neutropenia (12% patients), and diarrhea (14%). The median duration of responses was 9 months. The median time to disease progression was 6.8 months (range 0.4-18.1 months). Median survival was 13 months, and 54% of patients were alive at 1 year. We conclude that this new schedule of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced non-small-cell lung cancer.

AB - Weekly vinorelbine injection with cisplatin had been used in treatment of non-small-cell lung cancer. We performed a phase II trial to evaluate the efficacy and toxicity of a new schedule of vinorelbine and cisplatin in patients with previously untreated, inoperable (stage IIIB or stage IV) non- small-cell lung cancer. From April 1996 to May 1997, 52 patients were enrolled for study, and 50 patients were eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine, 30 mg/m2, intravenously on days 1 and 5 of a 21-day cycle, and cisplatin 100 mg/m2 (reduced to 80 mg/m2 after the first seven patients) given on day 1. A total of 211 treatment courses were administered; the median number of cycles administered per patient was 4.5 (range: 1-6), the median dose intensity for vinorelbine was 16.9 mg/m2/week (84.4%), whereas that of cisplatin was 22.8 mg/m2/week (84.7%). Twenty-five patients responded to therapy for an overall response rate of 50%; one patient attained a complete response (2%). The main toxicities were vomiting, myelosuppression, and diarrhea, which included World Health Organization grade 3 or 4 nausea/vomiting (58% patients), anemia (41% patients), neutropenia (12% patients), and diarrhea (14%). The median duration of responses was 9 months. The median time to disease progression was 6.8 months (range 0.4-18.1 months). Median survival was 13 months, and 54% of patients were alive at 1 year. We conclude that this new schedule of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced non-small-cell lung cancer.

KW - Cisplatin

KW - Non-small-cell lung cancer

KW - Phase II trial

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0034044240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034044240&partnerID=8YFLogxK

U2 - 10.1097/00000421-200002000-00017

DO - 10.1097/00000421-200002000-00017

M3 - Article

C2 - 10683080

AN - SCOPUS:0034044240

VL - 23

SP - 60

EP - 64

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -